Arachidonic acid metabolism in primary irritant dermatitis produced by patch testing of human skin with surfactants.
A clinical study was performed to determine the effects of patch testing human skin with four industrially used surfactants on erythema formation, transepidermal water loss, and the contents in suction blister fluids of primary proinflammatory mediators including arachidonic acid, eicosanoids, and IL-1 alpha, which were analyzed by quantitative gas chromatography/negative ion chemical ionization mass spectrometry and by an enzyme-immunoassay, respectively. Benzalkonium chloride (BKCI) and sodium lauryl sulfate (SLS) elicited erythema and caused increased transepidermal water loss, indicating a disturbance of the epidermal barrier. Triethanolamine (TEA) and Tween 80 did not evoke these gross symptoms of inflammation. Suction blister fluids collected after a 24-h application of BKCl, SLS, and Tween 80 contained significantly increased amounts of individual eicosanoids whereas TEA induced no response. The induced eicosanoid profile was characteristic for each compound, pointing to different cell types of skin to be involved in their production. The elevation of prostaglandin and LTB4 contents correlated with the induction of erythema and the impairment of the epidermal barrier as shown for BKCl and SLS and preceded the maximum of erythema formation. IL-1 alpha contents did not correlate with these gross symptoms of inflammation. The results of this in vivo study support those of a previous study using human keratinocytes in culture indicating the release of arachidonic acid and prostaglandins to be an early event involved in the interaction of keratinocytes with surfactants. Moreover, the in vivo data with human skin underscore the mechanistic relationship to the in vitro model and support the concept that arachidonic acid and eicosanoid release from keratinocytes can be used as a marker of primary skin irritation.
Müller-Decker
K
K
Deutsches Krebsforschungszentrum, Department Biochemistry of Tissue Specific Regulation, Berlin, Germany.
Heinzelmann
T
T
Fürstenberger
G
G
Kecskes
A
A
Lehmann
W D
WD
Marks
F
F
D000328:Adult; D016718:Arachidonic Acid / Q000378:metabolism*; D001548:Benzalkonium Compounds / Q000009:adverse effects; D017453:Dermatitis, Irritant / Q000209:etiology / Q000378:metabolism*; D015777:Eicosanoids / Q000378:metabolism; D004983:Ethanolamines / Q000009:adverse effects; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism; D008297:Male; D010328:Patch Tests; D011136:Polysorbates / Q000009:adverse effects; D012867:Skin / Q000187:drug effects* / Q000378:metabolism; D012967:Sodium Dodecyl Sulfate / Q000009:adverse effects; D013501:Surface-Active Agents / Q000009:adverse effects*; D014867:Water / Q000378:metabolism
D001548:Benzalkonium Compounds; D015777:Eicosanoids; D004983:Ethanolamines; D007375:Interleukin-1; D011136:Polysorbates; D013501:Surface-Active Agents; D014867:Water; D016718:Arachidonic Acid; D012967:Sodium Dodecyl Sulfate; C009546:triethanolamine